Home > Press Releases > Gene Therapy for Ultra-Rare Diseases Market

Gene Therapy for Ultra-Rare Diseases Market Likely to Surpass USD 0.7 Billion by 2035

Report Code: HC-610  |  Published in: Oct 2025, By MarketGenics  |  Number of pages: 399
Get PDF
Buy

A significant study discovering the market avenues on, “Gene Therapy for Ultra-Rare Diseases Market Size, Share & Trends Analysis Report by Vector Type (Viral Vectors, Non-Viral Vectors), Disease Type, Therapy Type, Route of Administration, Age Group, Product Stage, Technology Platform, Manufacturing Process, End-Users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035” A holistic view of the market pathways in the gene therapy for ultra-rare diseases  market underscores revenue acceleration through three key levers scalable product line extensions, high‑maturity strategic partnerships

Global Gene Therapy for Ultra-Rare Diseases Market Forecast 2035:

According to the report, the global gene therapy for ultra-rare diseases market is projected to expand from USD 0.3 billion in 2025 to USD 0.7 billion by 2035, registering a CAGR of 8.4%, the highest during the forecast period. The market of Gene Therapy of Ultra-Rare Diseases is growing at a rapid pace globally, driven by the improvement of viral and non-viral gene delivery approaches, the expansion of activities of CRISPR and other gene-editing technologies, and the increased focus on individualized medicine toward patients with ultra-rare genetic disorders. The increased occurrence of rare genetic diseases, in combination with more awareness in patients and a positive regulatory environment, is hastening the creation, clinical studies, and gains of new treatments.

North America is already the market leader because of its well-developed biotechnology base and the presence of excellent clinical research facilities and favorable orphan drug policies, and Europe and Asia-Pacific are also proving to be the high potential areas of expansion. Firms are also taking advantage of hospital and research partnerships as well as AI-based solutions to target discovery and design of patient-specific therapies to improve treatment effectiveness and safety. Viral vectors are leading because they have been demonstrated to be efficient and CRISPR-based therapies and non-viral systems are on the rise. Altogether, there exist tremendous opportunities in the market in relation to precision therapies, accelerated regulatory pathways, and enhanced patient outcomes in the management of ultra-rare diseases.

“Key Driver, Restraint, and Growth Opportunity Shaping the Global Gene Therapy for Ultra-Rare Diseases Market”

Growth in the market is being driven by the increasing incidence of ultra-rare genetic disorders and the patient demand of effective therapies. Long-term effects in therapy can be achieved by the use of advances in platforms of gene delivery such as viral vectors and highly specific gene-editing technologies. Additional encouragement of innovation and commercialization comes through government support, orphan drug development funding, and friendlier regulatory routes, allowing biotechnology firms to create therapies that fulfill unmet medical needs in ultra-rare disease populations around the globe.

Gene therapies are not accessible or adopted due to the high cost of development and treatment. The viral vectors and custom-made treatment are complicated production procedures demanding advanced infrastructure and expertise. Also, strict regulatory needs, possible immune reactions and safety issues in the long-term limit widespread implementation. The small numbers of patients with ultra-rare diseases pose a commercial challenge, especially in emerging markets, slowing the broad adoption despite the advancement of technologies and the increased clinical demand.

The growing interest on the combination therapies opens opportunities to improve the efficacy of gene therapies in ultra-rare diseases. Through combination of gene therapy and supportive pharmacological therapy or immunomodulatory therapy, companies are able to enhance patient outcomes and expand clinical applicability. Partnerships with pharmaceutical companies and clinical research institutes help to develop and receive regulatory approval, which allows manufacturers to increase market penetration and treat intricate ultra-rare diseases more efficiently.

Expansion of Global Gene Therapy for Ultra-Rare Diseases Market

“Innovation, and public funding propel the global gene therapy for ultra-rare diseases market expansion”

  • The market of gene therapy of ultra-rare diseases is experiencing a spectacular worldwide growth, which is mainly driven by the continuous development of the viral and non-viral systems of gene delivery, CRISPR, and other innovative technologies of gene-editing. These have been combined with personalized medicine strategies and targeted development of therapeutic solutions and are making possible effective management of previously incurable ultra-rare genetic diseases as well as improving patient-specific safety, efficacy, and long-term clinical outcomes. As an example, VG901 (AAV-based gene therapy against retinitis pigmentosa), an ultra-rare disease gene therapy candidate by ViGeneron GmbH was granted a U.S. Food and Drug Administration Rare Pediatric Disease Designation, which grants them the opportunity to expedite the review procedure and receive a priority status in this ultra-rare ocular disease.
  • Government and insurance incentives can significantly facilitate the adoption of gene therapy on ultra-rare diseases, since they are significant in reducing the high cost burden of the new types of treatment. An example is the U.S. Programs like the Orphan Drug Act offer tax breaks, funding as well as seven-year market exclusivity upon approval of an approved therapy to motivate firms to invest in research and development of conditions with very limited patient populations. Also, Ultragenyx became a member of the FDA and NIH Bespoke Gene Therapy Consortium (BGTC), a five-year and $76.5 million effort to bring pace to the creation of gene therapies to treat rare diseases. This is a public-private collaboration aimed at maximizing adeno-associated virus (AAV) vectors production and simplifying regulatory approval, respectively, to lower costs and time to market of treatments of ultra-rare conditions.

Regional Analysis of Global Gene Therapy for Ultra-Rare Diseases Market

  • The market that has the best opportunities is the gene therapy for ultra-rare diseases in North America because of the developed biotechnology ecosystem, the strong clinical research base, and the supportive regulatory climate. The orphan drug incentives by the U.S. Food and Drug Administration, the robust federal and private sector investments, promote innovation and early development. Top organizations like the NIH and the Center of Biologics Evaluation and Research of FDA also expand translational research, making breakthrough therapies in ultra-rare genetic disease more quickly approved and commercialized.
  • The Asia-Pacific, particularly the gene therapy for ultra-rare diseases market, will experience the best growth due to the emerging global healthcare infrastructure, the growing government efforts to fund research on rare diseases and the increasing number of Indian biotech-pharmaceutical collaboration projects on a global scale. Japan, China, and South Korea are among the countries that have been putting large investments in genomic medicine, CRISPR studies, and domestic production of viral vectors. Likewise, favourable regulatory changes and patient registries are boosting clinical trials approvals and market access. The increasing awareness, diagnostic capacity, and development of rare disease focal centers also make Asia-Pacific a prime growth centre in respect to developing advanced gene therapies.

Prominent players operating in the global gene therapy for ultra-rare diseases market are BioMarin Pharmaceutical Inc., Bluebird bio, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, CSL Behring, Editas Medicine, Inc., Intellia Therapeutics, Inc., Novartis AG, Orchard Therapeutics plc, Passage Bio, Inc., Pfizer Inc., Roche Holding AG, Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Spark Therapeutics (Roche), Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., uniQure N.V., Vertex Pharmaceuticals Incorporated, and Other Key Players.

The global Gene Therapy for Ultra-Rare Diseases market has been segmented as follows:

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Vector Type

  • Viral Vectors
    • Adeno-Associated Virus (AAV) Vectors
    • Lentiviral Vectors
    • Retroviral Vectors
    • Adenoviral Vectors
    • Herpes Simplex Virus (HSV) Vectors
    • Others
  • Non-Viral Vectors
    • Plasmid DNA
    • Lipid Nanoparticles
    • Electroporation-based
    • Naked DNA
    • Others

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Disease Type

  • Neurological Disorders
    • Spinal Muscular Atrophy (SMA)
    • Duchenne Muscular Dystrophy (DMD)
    • Huntington's Disease
    • Rett Syndrome
    • Batten Disease
    • Others
  • Hematological Disorders
    • Hemophilia A
    • Hemophilia B
    • Sickle Cell Disease
    • Beta-Thalassemia
    • Others
  • Metabolic Disorders
    • Lysosomal Storage Diseases
    • Gaucher Disease
    • Fabry Disease
    • Pompe Disease
    • Others
  • Ophthalmological Disorders
    • Leber Congenital Amaurosis
    • Retinitis Pigmentosa
    • Choroideremia
    • Others
  • Immunological Disorders
  • Cardiovascular Disorders
  • Others

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Therapy Type

  • In Vivo Gene Therapy
    • Directly Administered
    • Systemically Delivered
    • Others
  • Ex Vivo Gene Therapy
    • Cell-based Therapies
    • Tissue-engineered Products
    • Others
  • Gene Editing Therapies
    • CRISPR/Cas9
    • TALENs
    • Zinc Finger Nucleases
    • Others

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Route of Administration

  • Intravenous (IV)
  • Intramuscular (IM)
  • Intrathecal
  • Subretinal
  • Intravitreal
  • Direct Tissue Injection

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Age Group

  • Pediatric Patients
    • Neonates (0-1 month)
    • Infants (1 month - 2 years)
    • Children (2-12 years)
    • Adolescents (12-18 years)
  • Adult Patients
    • Young Adults (18-40 years)
    • Middle-aged Adults (40-65 years)
    • Elderly (65+ years)

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Product Stage

  • Approved Therapies
  • Clinical Stage
  • Phase I
  • Phase II
  • Phase III
  • Preclinical Stage
  • Research & Discovery Stage

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Technology Platform

  • AAV-based Platform
  • Lentiviral Platform
  • CRISPR-based Platform
  • Base Editing Platform
  • Prime Editing Platform
  • RNA Interference (RNAi)
  • Antisense Oligonucleotides

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Manufacturing Process

  • Autologous Manufacturing
  • Allogeneic Manufacturing
  • Contract Manufacturing
  • In-house Manufacturing

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, by End Use Industry

  • Hospitals & Clinics
    • Diagnostic Services
    • Treatment Administration
    • Patient Monitoring
    • Acute Care Management
    • Others
  • Specialty Treatment Centers
    • Gene Therapy Administration
    • Post-treatment Care
    • Clinical Trial Conduct
    • Patient Follow-up Programs
    • Others
  • Research & Academic Institutions
    • Clinical Research
    • Drug Development
    • Biomarker Discovery
    • Preclinical Studies
    • Others
  • Biotechnology & Pharmaceutical Companies
    • Product Development
    • Manufacturing & Production
    • Quality Control
    • Regulatory Compliance
    • Others
  • Contract Research Organizations (CROs)
    • Clinical Trial Management
    • Data Analysis
    • Regulatory Support
    • Patient Recruitment
    • Others
  • Gene Therapy Manufacturing Facilities
    • Vector Production
    • Cell Processing
    • Quality Assurance
    • Supply Chain Management
    • Others

Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
  • South America

About Us

MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.

We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.

Contact Us

USA Address:

800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.

+1(302)303-2617

info@marketgenics.co

India Address:

3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.

sales@marketgenics.co

Table of Contents

  • 1. Research Methodology and Assumptions
    • 1.1. Definitions
    • 1.2. Research Design and Approach
    • 1.3. Data Collection Methods
    • 1.4. Base Estimates and Calculations
    • 1.5. Forecasting Models
      • 1.5.1. Key Forecast Factors & Impact Analysis
    • 1.6. Secondary Research
      • 1.6.1. Open Sources
      • 1.6.2. Paid Databases
      • 1.6.3. Associations
    • 1.7. Primary Research
      • 1.7.1. Primary Sources
      • 1.7.2. Primary Interviews with Stakeholders across Ecosystem
  • 2. Executive Summary
    • 2.1. Global Gene Therapy for Ultra-Rare Diseases Market Outlook
      • 2.1.1. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), and Forecasts, 2021-2035
      • 2.1.2. Compounded Annual Growth Rate Analysis
      • 2.1.3. Growth Opportunity Analysis
      • 2.1.4. Segmental Share Analysis
      • 2.1.5. Geographical Share Analysis
    • 2.2. Market Analysis and Facts
    • 2.3. Supply-Demand Analysis
    • 2.4. Competitive Benchmarking
    • 2.5. Go-to- Market Strategy
      • 2.5.1. Customer/ End-use Industry Assessment
      • 2.5.2. Growth Opportunity Data, 2025-2035
        • 2.5.2.1. Regional Data
        • 2.5.2.2. Country Data
        • 2.5.2.3. Segmental Data
      • 2.5.3. Identification of Potential Market Spaces
      • 2.5.4. GAP Analysis
      • 2.5.5. Potential Attractive Price Points
      • 2.5.6. Prevailing Market Risks & Challenges
      • 2.5.7. Preferred Sales & Marketing Strategies
      • 2.5.8. Key Recommendations and Analysis
      • 2.5.9. A Way Forward
  • 3. Industry Data and Premium Insights
    • 3.1. Global Healthcare & Pharmaceutical Industry Overview, 2025
      • 3.1.1. Healthcare & Pharmaceutical Industry Ecosystem Analysis
      • 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
      • 3.1.3. Regional Distribution for Healthcare & Pharmaceutical Industry
    • 3.2. Supplier Customer Data
    • 3.3. Technology Roadmap and Developments
    • 3.4. Trade Analysis
      • 3.4.1. Import & Export Analysis, 2025
      • 3.4.2. Top Importing Countries
      • 3.4.3. Top Exporting Countries
    • 3.5. Trump Tariff Impact Analysis
      • 3.5.1. Manufacturer
        • 3.5.1.1. Based on the component & Raw material
      • 3.5.2. Supply Chain
      • 3.5.3. End Consumer
    • 3.6. Raw Material Analysis
  • 4. Market Overview
    • 4.1. Market Dynamics
      • 4.1.1. Drivers
        • 4.1.1.1. Increasing prevalence and diagnosis of ultra-rare genetic disorders
        • 4.1.1.2. Advancements in viral and non-viral gene delivery technologies
        • 4.1.1.3. Supportive regulatory frameworks and orphan drug incentives
      • 4.1.2. Restraints
        • 4.1.2.1. High cost of therapy development and treatment limiting patient access
        • 4.1.2.2. Challenges in large-scale manufacturing and quality control of gene therapies
    • 4.2. Key Trend Analysis
    • 4.3. Regulatory Framework
      • 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
      • 4.3.2. Tariffs and Standards
      • 4.3.3. Impact Analysis of Regulations on the Market
    • 4.4. Value Chain Analysis
      • 4.4.1. Research & Development
      • 4.4.2. Preclinical & Clinical Development
      • 4.4.3. Manufacturing & Production
      • 4.4.4. Distributors/ Commercializers
      • 4.4.5. End-users/ Customers
    • 4.5. Porter’s Five Forces Analysis
    • 4.6. PESTEL Analysis
    • 4.7. Global Gene Therapy for Ultra-Rare Diseases Market Demand
      • 4.7.1. Historical Market Size - in Value (US$ Bn), 2020-2024
      • 4.7.2. Current and Future Market Size - in Value (US$ Bn), 2025–2035
        • 4.7.2.1. Y-o-Y Growth Trends
        • 4.7.2.2. Absolute $ Opportunity Assessment
  • 5. Competition Landscape
    • 5.1. Competition structure
      • 5.1.1. Fragmented v/s consolidated
    • 5.2. Company Share Analysis, 2025
      • 5.2.1. Global Company Market Share
      • 5.2.2. By Region
        • 5.2.2.1. North America
        • 5.2.2.2. Europe
        • 5.2.2.3. Asia Pacific
        • 5.2.2.4. Middle East
        • 5.2.2.5. Africa
        • 5.2.2.6. South America
    • 5.3. Product Comparison Matrix
      • 5.3.1. Specifications
      • 5.3.2. Market Positioning
      • 5.3.3. Pricing
  • 6. Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Vector Type
    • 6.1. Key Segment Analysis
    • 6.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, Vector Type, 2021-2035
      • 6.2.1. Viral Vectors
        • 6.2.1.1. Adeno-Associated Virus (AAV) Vectors
        • 6.2.1.2. Lentiviral Vectors
        • 6.2.1.3. Retroviral Vectors
        • 6.2.1.4. Adenoviral Vectors
        • 6.2.1.5. Herpes Simplex Virus (HSV) Vectors
        • 6.2.1.6. Others
      • 6.2.2. Non-Viral Vectors
        • 6.2.2.1. Plasmid DNA
        • 6.2.2.2. Lipid Nanoparticles
        • 6.2.2.3. Electroporation-based
        • 6.2.2.4. Naked DNA
        • 6.2.2.5. Others
  • 7. Global Gene Therapy for Ultra-Rare Diseases Market Analysis, By Disease Type
    • 7.1. Key Segment Analysis
    • 7.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, Disease Type, 2021-2035
      • 7.2.1. Neurological Disorders
        • 7.2.1.1. Spinal Muscular Atrophy (SMA)
        • 7.2.1.2. Duchenne Muscular Dystrophy (DMD)
        • 7.2.1.3. Huntington's Disease
        • 7.2.1.4. Rett Syndrome
        • 7.2.1.5. Batten Disease
        • 7.2.1.6. Others
      • 7.2.2. Hematological Disorders
        • 7.2.2.1. Hemophilia A
        • 7.2.2.2. Hemophilia B
        • 7.2.2.3. Sickle Cell Disease
        • 7.2.2.4. Beta-Thalassemia
        • 7.2.2.5. Others
      • 7.2.3. Metabolic Disorders
        • 7.2.3.1. Lysosomal Storage Diseases
        • 7.2.3.2. Gaucher Disease
        • 7.2.3.3. Fabry Disease
        • 7.2.3.4. Pompe Disease
        • 7.2.3.5. Others
      • 7.2.4. Ophthalmological Disorders
        • 7.2.4.1. Leber Congenital Amaurosis
        • 7.2.4.2. Retinitis Pigmentosa
        • 7.2.4.3. Choroideremia
        • 7.2.4.4. Others
      • 7.2.5. Immunological Disorders
      • 7.2.6. Cardiovascular Disorders
      • 7.2.7. Others
  • 8. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts,By Therapy Type
    • 8.1. Key Findings
    • 8.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, Therapy Type, 2021-2035
      • 8.2.1. In Vivo Gene Therapy
        • 8.2.1.1. Directly Administered
        • 8.2.1.2. Systemically Delivered
        • 8.2.1.3. Others
      • 8.2.2. Ex Vivo Gene Therapy
        • 8.2.2.1. Cell-based Therapies
        • 8.2.2.2. Tissue-engineered Products
        • 8.2.2.3. Others
      • 8.2.3. Gene Editing Therapies
        • 8.2.3.1. CRISPR/Cas9
        • 8.2.3.2. TALENs
        • 8.2.3.3. Zinc Finger Nucleases
      • 8.2.4. Others
  • 9. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, By Route of Administration
    • 9.1. Key Findings
    • 9.2. Gene Therapy for Ultra-Rare Diseases Market Size (Vo Value - US$ Mn), Analysis, and Forecasts, By Route of Administration, 2021-2035
      • 9.2.1. Intravenous (IV)
      • 9.2.2. Intramuscular (IM)
      • 9.2.3. Intrathecal
      • 9.2.4. Subretinal
      • 9.2.5. Intravitreal
      • 9.2.6. Direct Tissue Injection
  • 10. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, By Age Group
    • 10.1. Key Findings
    • 10.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, Age Group, 2021-2035
      • 10.2.1. Pediatric Patients
        • 10.2.1.1. Neonates (0-1 month)
        • 10.2.1.2. Infants (1 month - 2 years)
        • 10.2.1.3. Children (2-12 years)
        • 10.2.1.4. Adolescents (12-18 years)
      • 10.2.2. Adult Patients
        • 10.2.2.1. Young Adults (18-40 years)
        • 10.2.2.2. Middle-aged Adults (40-65 years)
        • 10.2.2.3. Elderly (65+ years)
  • 11. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, By Product Stage
    • 11.1. Key Findings
    • 11.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, By Product Stage, 2021-2035
      • 11.2.1. Approved Therapies
      • 11.2.2. Clinical Stage
        • 11.2.2.1. Phase I
        • 11.2.2.2. Phase II
        • 11.2.2.3. Phase III
      • 11.2.3. Preclinical Stage
      • 11.2.4. Research & Discovery Stage
  • 12. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, By Technology Platform
    • 12.1. Key Findings
    • 12.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, Technology Platform, 2021-2035
      • 12.2.1. AAV-based Platform
      • 12.2.2. Lentiviral Platform
      • 12.2.3. CRISPR-based Platform
      • 12.2.4. Base Editing Platform
      • 12.2.5. Prime Editing Platform
      • 12.2.6. RNA Interference (RNAi)
      • 12.2.7. Antisense Oligonucleotides
  • 13. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, By Manufacturing Process
    • 13.1. Key Findings
    • 13.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, By Manufacturing Process, 2021-2035
      • 13.2.1. Autologous Manufacturing
      • 13.2.2. Allogeneic Manufacturing
      • 13.2.3. Contract Manufacturing
      • 13.2.4. In-house Manufacturing
  • 14. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, By End-users
    • 14.1. Key Findings
    • 14.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, By End-users, 2021-2035
      • 14.2.1. Hospitals & Clinics
        • 14.2.1.1. Diagnostic Services
        • 14.2.1.2. Treatment Administration
        • 14.2.1.3. Patient Monitoring
        • 14.2.1.4. Acute Care Management
        • 14.2.1.5. Others
      • 14.2.2. Specialty Treatment Centers
        • 14.2.2.1. Gene Therapy Administration
        • 14.2.2.2. Post-treatment Care
        • 14.2.2.3. Clinical Trial Conduct
        • 14.2.2.4. Patient Follow-up Programs
        • 14.2.2.5. Others
      • 14.2.3. Research & Academic Institutions
        • 14.2.3.1. Clinical Research
        • 14.2.3.2. Drug Development
        • 14.2.3.3. Biomarker Discovery
        • 14.2.3.4. Preclinical Studies
        • 14.2.3.5. Others
      • 14.2.4. Biotechnology & Pharmaceutical Companies
        • 14.2.4.1. Product Development
        • 14.2.4.2. Manufacturing & Production
        • 14.2.4.3. Quality Control
        • 14.2.4.4. Regulatory Compliance
        • 14.2.4.5. Others
      • 14.2.5. Contract Research Organizations (CROs)
        • 14.2.5.1. Clinical Trial Management
        • 14.2.5.2. Data Analysis
        • 14.2.5.3. Regulatory Support
        • 14.2.5.4. Patient Recruitment
        • 14.2.5.5. Others
      • 14.2.6. Gene Therapy Manufacturing Facilities
        • 14.2.6.1. Vector Production
        • 14.2.6.2. Cell Processing
        • 14.2.6.3. Quality Assurance
        • 14.2.6.4. Supply Chain Management
        • 14.2.6.5. Others
  • 15. Global Gene Therapy for Ultra-Rare Diseases Market Analysis and Forecasts, by Region
    • 15.1. Key Findings
    • 15.2. Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Mn), Analysis, and Forecasts, by Region, 2021-2035
      • 15.2.1. North America
      • 15.2.2. Europe
      • 15.2.3. Asia Pacific
      • 15.2.4. Middle East
      • 15.2.5. Africa
      • 15.2.6. South America
  • 16. North America Gene Therapy for Ultra-Rare Diseases Market Analysis
    • 16.1. Key Segment Analysis
    • 16.2. Regional Snapshot
    • 16.3. North America Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 16.3.1. Vector Type
      • 16.3.2. Disease Type
      • 16.3.3. Therapy Type
      • 16.3.4. Route of Administration
      • 16.3.5. Age Group
      • 16.3.6. Product Stage
      • 16.3.7. Manufacturing Process
      • 16.3.8. End-Users
      • 16.3.9. Country
        • 16.3.9.1. USA
        • 16.3.9.2. Canada
        • 16.3.9.3. Mexico
    • 16.4. USA Gene Therapy for Ultra-Rare Diseases Market
      • 16.4.1. Country Segmental Analysis
      • 16.4.2. Vector Type
      • 16.4.3. Disease Type
      • 16.4.4. Therapy Type
      • 16.4.5. Route of Administration
      • 16.4.6. Age Group
      • 16.4.7. Product Stage
      • 16.4.8. Manufacturing Process
      • 16.4.9. End-Users
    • 16.5. Canada Gene Therapy for Ultra-Rare Diseases Market
      • 16.5.1. Country Segmental Analysis
      • 16.5.2. Vector Type
      • 16.5.3. Disease Type
      • 16.5.4. Therapy Type
      • 16.5.5. Route of Administration
      • 16.5.6. Age Group
      • 16.5.7. Product Stage
      • 16.5.8. Manufacturing Process
      • 16.5.9. End-Users
    • 16.6. Mexico Gene Therapy for Ultra-Rare Diseases Market
      • 16.6.1. Country Segmental Analysis
      • 16.6.2. Vector Type
      • 16.6.3. Disease Type
      • 16.6.4. Therapy Type
      • 16.6.5. Route of Administration
      • 16.6.6. Age Group
      • 16.6.7. Product Stage
      • 16.6.8. Manufacturing Process
      • 16.6.9. End-Users
  • 17. Europe Gene Therapy for Ultra-Rare Diseases Market Analysis
    • 17.1. Key Segment Analysis
    • 17.2. Regional Snapshot
    • 17.3. Europe Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 17.3.1. Therapeutic Application
      • 17.3.2. Vector Type
      • 17.3.3. Disease Type
      • 17.3.4. Therapy Type
      • 17.3.5. Route of Administration
      • 17.3.6. Age Group
      • 17.3.7. Product Stage
      • 17.3.8. Manufacturing Process
      • 17.3.9. End-Users
        • 17.3.9.1. Germany
        • 17.3.9.2. United Kingdom
        • 17.3.9.3. France
        • 17.3.9.4. Italy
        • 17.3.9.5. Spain
        • 17.3.9.6. Netherlands
        • 17.3.9.7. Nordic Countries
        • 17.3.9.8. Poland
        • 17.3.9.9. Russia & CIS
        • 17.3.9.10. Rest of Europe
    • 17.4. Germany Gene Therapy for Ultra-Rare Diseases Market
      • 17.4.1. Country Segmental Analysis
      • 17.4.2. Vector Type
      • 17.4.3. Disease Type
      • 17.4.4. Therapy Type
      • 17.4.5. Route of Administration
      • 17.4.6. Age Group
      • 17.4.7. Product Stage
      • 17.4.8. Manufacturing Process
      • 17.4.9. End-Users
    • 17.5. United Kingdom Gene Therapy for Ultra-Rare Diseases Market
      • 17.5.1. Country Segmental Analysis
      • 17.5.2. Vector Type
      • 17.5.3. Disease Type
      • 17.5.4. Therapy Type
      • 17.5.5. Route of Administration
      • 17.5.6. Age Group
      • 17.5.7. Product Stage
      • 17.5.8. Manufacturing Process
      • 17.5.9. End-Users
    • 17.6. France Gene Therapy for Ultra-Rare Diseases Market
      • 17.6.1. Country Segmental Analysis
      • 17.6.2. Vector Type
      • 17.6.3. Disease Type
      • 17.6.4. Therapy Type
      • 17.6.5. Route of Administration
      • 17.6.6. Age Group
      • 17.6.7. Product Stage
      • 17.6.8. Manufacturing Process
      • 17.6.9. End-Users
    • 17.7. Italy Gene Therapy for Ultra-Rare Diseases Market
      • 17.7.1. Country Segmental Analysis
      • 17.7.2. Vector Type
      • 17.7.3. Disease Type
      • 17.7.4. Therapy Type
      • 17.7.5. Route of Administration
      • 17.7.6. Age Group
      • 17.7.7. Product Stage
      • 17.7.8. Manufacturing Process
      • 17.7.9. End-Users
    • 17.8. Spain Gene Therapy for Ultra-Rare Diseases Market
      • 17.8.1. Therapeutic Application
      • 17.8.2. Vector Type
      • 17.8.3. Disease Type
      • 17.8.4. Therapy Type
      • 17.8.5. Route of Administration
      • 17.8.6. Age Group
      • 17.8.7. Product Stage
      • 17.8.8. Manufacturing Process
      • 17.8.9. End-Users
    • 17.9. Netherlands Gene Therapy for Ultra-Rare Diseases Market
      • 17.9.1. Country Segmental Analysis
      • 17.9.2. Vector Type
      • 17.9.3. Disease Type
      • 17.9.4. Therapy Type
      • 17.9.5. Route of Administration
      • 17.9.6. Age Group
      • 17.9.7. Product Stage
      • 17.9.8. Manufacturing Process
      • 17.9.9. End-Users
    • 17.10. Nordic Countries Gene Therapy for Ultra-Rare Diseases Market
      • 17.10.1. Country Segmental Analysis
      • 17.10.2. Vector Type
      • 17.10.3. Disease Type
      • 17.10.4. Therapy Type
      • 17.10.5. Route of Administration
      • 17.10.6. Age Group
      • 17.10.7. Product Stage
      • 17.10.8. Manufacturing Process
      • 17.10.9. End-Users
    • 17.11. Poland Gene Therapy for Ultra-Rare Diseases Market
      • 17.11.1. Country Segmental Analysis
      • 17.11.2. Vector Type
      • 17.11.3. Disease Type
      • 17.11.4. Therapy Type
      • 17.11.5. Route of Administration
      • 17.11.6. Age Group
      • 17.11.7. Product Stage
      • 17.11.8. Manufacturing Process
      • 17.11.9. End-Users
    • 17.12. Russia & CIS Gene Therapy for Ultra-Rare Diseases Market
      • 17.12.1. Country Segmental Analysis
      • 17.12.2. Vector Type
      • 17.12.3. Disease Type
      • 17.12.4. Therapy Type
      • 17.12.5. Route of Administration
      • 17.12.6. Age Group
      • 17.12.7. Product Stage
      • 17.12.8. Manufacturing Process
      • 17.12.9. End-Users
    • 17.13. Rest of Europe Gene Therapy for Ultra-Rare Diseases Market
      • 17.13.1. Country Segmental Analysis
      • 17.13.2. Vector Type
      • 17.13.3. Disease Type
      • 17.13.4. Therapy Type
      • 17.13.5. Route of Administration
      • 17.13.6. Age Group
      • 17.13.7. Product Stage
      • 17.13.8. Manufacturing Process
      • 17.13.9. End-Users
  • 18. Asia Pacific Gene Therapy for Ultra-Rare Diseases Market Analysis
    • 18.1. Key Segment Analysis
    • 18.2. Regional Snapshot
    • 18.3. East Asia Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 18.3.1. Therapeutic Application
      • 18.3.2. Vector Type
      • 18.3.3. Disease Type
      • 18.3.4. Therapy Type
      • 18.3.5. Route of Administration
      • 18.3.6. Age Group
      • 18.3.7. Product Stage
      • 18.3.8. Manufacturing Process
      • 18.3.9. End-Users
      • 18.3.10. Country
        • 18.3.10.1. China
        • 18.3.10.2. India
        • 18.3.10.3. Japan
        • 18.3.10.4. South Korea
        • 18.3.10.5. Australia and New Zealand
        • 18.3.10.6. Indonesia
        • 18.3.10.7. Malaysia
        • 18.3.10.8. Thailand
        • 18.3.10.9. Vietnam
        • 18.3.10.10. Rest of Asia Pacific
    • 18.4. China Gene Therapy for Ultra-Rare Diseases Market
      • 18.4.1. Country Segmental Analysis
      • 18.4.2. Vector Type
      • 18.4.3. Disease Type
      • 18.4.4. Therapy Type
      • 18.4.5. Route of Administration
      • 18.4.6. Age Group
      • 18.4.7. Product Stage
      • 18.4.8. Manufacturing Process
      • 18.4.9. End-Users
    • 18.5. India Gene Therapy for Ultra-Rare Diseases Market
      • 18.5.1. Country Segmental Analysis
      • 18.5.2. Vector Type
      • 18.5.3. Disease Type
      • 18.5.4. Therapy Type
      • 18.5.5. Route of Administration
      • 18.5.6. Age Group
      • 18.5.7. Product Stage
      • 18.5.8. Manufacturing Process
      • 18.5.9. End-Users
    • 18.6. Japan Gene Therapy for Ultra-Rare Diseases Market
      • 18.6.1. Country Segmental Analysis
      • 18.6.2. Vector Type
      • 18.6.3. Disease Type
      • 18.6.4. Therapy Type
      • 18.6.5. Route of Administration
      • 18.6.6. Age Group
      • 18.6.7. Product Stage
      • 18.6.8. Manufacturing Process
      • 18.6.9. End-Users
    • 18.7. South Korea Gene Therapy for Ultra-Rare Diseases Market
      • 18.7.1. Country Segmental Analysis
      • 18.7.2. Vector Type
      • 18.7.3. Disease Type
      • 18.7.4. Therapy Type
      • 18.7.5. Route of Administration
      • 18.7.6. Age Group
      • 18.7.7. Product Stage
      • 18.7.8. Manufacturing Process
      • 18.7.9. End-Users
    • 18.8. Australia and New Zealand Gene Therapy for Ultra-Rare Diseases Market
      • 18.8.1. Country Segmental Analysis
      • 18.8.2. Vector Type
      • 18.8.3. Disease Type
      • 18.8.4. Therapy Type
      • 18.8.5. Route of Administration
      • 18.8.6. Age Group
      • 18.8.7. Product Stage
      • 18.8.8. Manufacturing Process
      • 18.8.9. End-Users
    • 18.9. Indonesia Gene Therapy for Ultra-Rare Diseases Market
      • 18.9.1. Country Segmental Analysis
      • 18.9.2. Vector Type
      • 18.9.3. Disease Type
      • 18.9.4. Therapy Type
      • 18.9.5. Route of Administration
      • 18.9.6. Age Group
      • 18.9.7. Product Stage
      • 18.9.8. Manufacturing Process
      • 18.9.9. End-Users
    • 18.10. Malaysia Gene Therapy for Ultra-Rare Diseases Market
      • 18.10.1. Country Segmental Analysis
      • 18.10.2. Vector Type
      • 18.10.3. Disease Type
      • 18.10.4. Therapy Type
      • 18.10.5. Route of Administration
      • 18.10.6. Age Group
      • 18.10.7. Product Stage
      • 18.10.8. Manufacturing Process
      • 18.10.9. End-Users
    • 18.11. Thailand Gene Therapy for Ultra-Rare Diseases Market
      • 18.11.1. Country Segmental Analysis
      • 18.11.2. Vector Type
      • 18.11.3. Disease Type
      • 18.11.4. Therapy Type
      • 18.11.5. Route of Administration
      • 18.11.6. Age Group
      • 18.11.7. Product Stage
      • 18.11.8. Manufacturing Process
      • 18.11.9. End-Users
    • 18.12. Vietnam Gene Therapy for Ultra-Rare Diseases Market
      • 18.12.1. Country Segmental Analysis
      • 18.12.2. Vector Type
      • 18.12.3. Disease Type
      • 18.12.4. Therapy Type
      • 18.12.5. Route of Administration
      • 18.12.6. Age Group
      • 18.12.7. Product Stage
      • 18.12.8. Manufacturing Process
      • 18.12.9. End-Users
    • 18.13. Rest of Asia Pacific Gene Therapy for Ultra-Rare Diseases Market
      • 18.13.1. Country Segmental Analysis
      • 18.13.2. Vector Type
      • 18.13.3. Disease Type
      • 18.13.4. Therapy Type
      • 18.13.5. Route of Administration
      • 18.13.6. Age Group
      • 18.13.7. Product Stage
      • 18.13.8. Manufacturing Process
      • 18.13.9. End-Users
  • 19. Middle East Gene Therapy for Ultra-Rare Diseases Market Analysis
    • 19.1. Key Segment Analysis
    • 19.2. Regional Snapshot
    • 19.3. Middle East Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 19.3.1. Therapeutic Application
      • 19.3.2. Vector Type
      • 19.3.3. Disease Type
      • 19.3.4. Therapy Type
      • 19.3.5. Route of Administration
      • 19.3.6. Age Group
      • 19.3.7. Product Stage
      • 19.3.8. Manufacturing Process
      • 19.3.9. End-Users
      • 19.3.10. Country
        • 19.3.10.1. Turkey
        • 19.3.10.2. UAE
        • 19.3.10.3. Saudi Arabia
        • 19.3.10.4. Israel
        • 19.3.10.5. Rest of Middle East
    • 19.4. Turkey Gene Therapy for Ultra-Rare Diseases Market
      • 19.4.1. Country Segmental Analysis
      • 19.4.2. Vector Type
      • 19.4.3. Disease Type
      • 19.4.4. Therapy Type
      • 19.4.5. Route of Administration
      • 19.4.6. Age Group
      • 19.4.7. Product Stage
      • 19.4.8. Manufacturing Process
      • 19.4.9. End-Users
    • 19.5. UAE Gene Therapy for Ultra-Rare Diseases Market
      • 19.5.1. Country Segmental Analysis
      • 19.5.2. Vector Type
      • 19.5.3. Disease Type
      • 19.5.4. Therapy Type
      • 19.5.5. Route of Administration
      • 19.5.6. Age Group
      • 19.5.7. Product Stage
      • 19.5.8. Manufacturing Process
      • 19.5.9. End-Users
    • 19.6. Saudi Arabia Gene Therapy for Ultra-Rare Diseases Market
      • 19.6.1. Country Segmental Analysis
      • 19.6.2. Vector Type
      • 19.6.3. Disease Type
      • 19.6.4. Therapy Type
      • 19.6.5. Route of Administration
      • 19.6.6. Age Group
      • 19.6.7. Product Stage
      • 19.6.8. Manufacturing Process
      • 19.6.9. End-Users
    • 19.7. Israel Gene Therapy for Ultra-Rare Diseases Market
      • 19.7.1. Country Segmental Analysis
      • 19.7.2. Vector Type
      • 19.7.3. Disease Type
      • 19.7.4. Therapy Type
      • 19.7.5. Route of Administration
      • 19.7.6. Age Group
      • 19.7.7. Product Stage
      • 19.7.8. Manufacturing Process
      • 19.7.9. End-Users
    • 19.8. Rest of Middle East Gene Therapy for Ultra-Rare Diseases Market
      • 19.8.1. Country Segmental Analysis
      • 19.8.2. Vector Type
      • 19.8.3. Disease Type
      • 19.8.4. Therapy Type
      • 19.8.5. Route of Administration
      • 19.8.6. Age Group
      • 19.8.7. Product Stage
      • 19.8.8. Manufacturing Process
      • 19.8.9. End-Users
  • 20. Africa Gene Therapy for Ultra-Rare Diseases Market Analysis
    • 20.1. Key Segment Analysis
    • 20.2. Regional Snapshot
    • 20.3. Africa Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 20.3.1. Therapeutic Application
      • 20.3.2. Vector Type
      • 20.3.3. Disease Type
      • 20.3.4. Therapy Type
      • 20.3.5. Route of Administration
      • 20.3.6. Age Group
      • 20.3.7. Product Stage
      • 20.3.8. Manufacturing Process
      • 20.3.9. End-Users
      • 20.3.10. Country
        • 20.3.10.1. South Africa
        • 20.3.10.2. Egypt
        • 20.3.10.3. Nigeria
        • 20.3.10.4. Algeria
        • 20.3.10.5. Rest of Africa
    • 20.4. South Africa Gene Therapy for Ultra-Rare Diseases Market
      • 20.4.1. Country Segmental Analysis
      • 20.4.2. Vector Type
      • 20.4.3. Disease Type
      • 20.4.4. Therapy Type
      • 20.4.5. Route of Administration
      • 20.4.6. Age Group
      • 20.4.7. Product Stage
      • 20.4.8. Manufacturing Process
      • 20.4.9. End-Users
    • 20.5. Egypt Gene Therapy for Ultra-Rare Diseases Market
      • 20.5.1. Country Segmental Analysis
      • 20.5.2. Vector Type
      • 20.5.3. Disease Type
      • 20.5.4. Therapy Type
      • 20.5.5. Route of Administration
      • 20.5.6. Age Group
      • 20.5.7. Product Stage
      • 20.5.8. Manufacturing Process
      • 20.5.9. End-Users
    • 20.6. Nigeria Gene Therapy for Ultra-Rare Diseases Market
      • 20.6.1. Country Segmental Analysis
      • 20.6.2. Vector Type
      • 20.6.3. Disease Type
      • 20.6.4. Therapy Type
      • 20.6.5. Route of Administration
      • 20.6.6. Age Group
      • 20.6.7. Product Stage
      • 20.6.8. Manufacturing Process
      • 20.6.9. End-Users
    • 20.7. Algeria Gene Therapy for Ultra-Rare Diseases Market
      • 20.7.1. Country Segmental Analysis
      • 20.7.2. Vector Type
      • 20.7.3. Disease Type
      • 20.7.4. Therapy Type
      • 20.7.5. Route of Administration
      • 20.7.6. Age Group
      • 20.7.7. Product Stage
      • 20.7.8. Manufacturing Process
      • 20.7.9. End-Users
    • 20.8. Rest of Africa Gene Therapy for Ultra-Rare Diseases Market
      • 20.8.1. Country Segmental Analysis
      • 20.8.2. Vector Type
      • 20.8.3. Disease Type
      • 20.8.4. Therapy Type
      • 20.8.5. Route of Administration
      • 20.8.6. Age Group
      • 20.8.7. Product Stage
      • 20.8.8. Manufacturing Process
      • 20.8.9. End-Users
  • 21. South America Gene Therapy for Ultra-Rare Diseases Market Analysis
    • 21.1. Key Segment Analysis
    • 21.2. Regional Snapshot
    • 21.3. Central and South Africa Gene Therapy for Ultra-Rare Diseases Market Size (Value - US$ Bn), Analysis, and Forecasts, 2021-2035
      • 21.3.1. Vector Type
      • 21.3.2. Disease Type
      • 21.3.3. Therapy Type
      • 21.3.4. Route of Administration
      • 21.3.5. Age Group
      • 21.3.6. Product Stage
      • 21.3.7. Manufacturing Process
      • 21.3.8. End-Users
      • 21.3.9. Country
        • 21.3.9.1. Brazil
        • 21.3.9.2. Argentina
        • 21.3.9.3. Rest of South America
    • 21.4. Brazil Gene Therapy for Ultra-Rare Diseases Market
      • 21.4.1. Country Segmental Analysis
      • 21.4.2. Vector Type
      • 21.4.3. Disease Type
      • 21.4.4. Therapy Type
      • 21.4.5. Route of Administration
      • 21.4.6. Age Group
      • 21.4.7. Product Stage
      • 21.4.8. Manufacturing Process
      • 21.4.9. End-Users
    • 21.5. Argentina Gene Therapy for Ultra-Rare Diseases Market
      • 21.5.1. Country Segmental Analysis
      • 21.5.2. Vector Type
      • 21.5.3. Disease Type
      • 21.5.4. Therapy Type
      • 21.5.5. Route of Administration
      • 21.5.6. Age Group
      • 21.5.7. Product Stage
      • 21.5.8. Manufacturing Process
      • 21.5.9. End-Users
    • 21.6. Rest of South America Gene Therapy for Ultra-Rare Diseases Market
      • 21.6.1. Country Segmental Analysis
      • 21.6.2. Vector Type
      • 21.6.3. Disease Type
      • 21.6.4. Therapy Type
      • 21.6.5. Route of Administration
      • 21.6.6. Age Group
      • 21.6.7. Product Stage
      • 21.6.8. Manufacturing Process
      • 21.6.9. End-Users
  • 22. Key Players/ Company Profile
    • 22.1. BioMarin Pharmaceutical Inc.
      • 22.1.1. Company Details/ Overview
      • 22.1.2. Company Financials
      • 22.1.3. Key Customers and Competitors
      • 22.1.4. Business/ Industry Portfolio
      • 22.1.5. Product Portfolio/ Specification Details
      • 22.1.6. Pricing Data
      • 22.1.7. Strategic Overview
      • 22.1.8. Recent Developments
    • 22.2. Bluebird bio, Inc.
    • 22.3. Bristol Myers Squibb Company
    • 22.4. CRISPR Therapeutics AG
    • 22.5. CSL Behring
    • 22.6. Editas Medicine, Inc.
    • 22.7. Intellia Therapeutics, Inc.
    • 22.8. Novartis AG
    • 22.9. Orchard Therapeutics plc
    • 22.10. Passage Bio, Inc.
    • 22.11. Pfizer Inc.
    • 22.12. Roche Holding AG
    • 22.13. Sangamo Therapeutics, Inc.
    • 22.14. Sarepta Therapeutics, Inc.
    • 22.15. Spark Therapeutics (Roche)
    • 22.16. Takeda Pharmaceutical Company Limited
    • 22.17. Ultragenyx Pharmaceutical Inc.
    • 22.18. uniQure N.V.
    • 22.19. Vertex Pharmaceuticals Incorporated
    • 22.20. Other Key Players

Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography

Get PDF
PRICING DETAILS
USD 4150
USD 5950
USD 7750
Related Report  
YOU MAY ALSO LIKE
Algae Protein Market by Source Type, Form, Protein Content, Production Method, Nature, Extraction Technology, Grade, End-Use Industry, and Geography
Alternative Protein Market by Source/Type, Form, Product Type, Processing Technology, Distribution Channel, Protein Content, End-users, and Geography
Astaxanthin Market by Source/Origin, Form, Grade/Purity Level, Concentration Level, Production Technology, End-users, Distribution Channel, Packaging Type, and Geography
Discount On Multiple Reports

Where did We Help Most?

Custom Market Research Services

We will customise the research for you, in case the report listed above does not meet your requirements.

Get 10% Free Customisation